SU
Sunil Healthcare Ltd (SUNLOC)
₹70.00
Mkt cap
₹75 Cr
P/E ratio
25.60
P/B
0.99
Div yield
0.00%
ROE
6.01%
ROCE
6.43%
EPS (TTM)
₹2.73
Book value
₹71
52W range
5–84
Sector
Healthcare
Price history
Previous close
Incorporated in 1976, Sunil Healthcare Ltd is a certified manufacturer of Empty Hard Gelatin capsules shell and HPMC Capsules shell. [1]
NSE SUNLOCBSE 537253
Health check
Cautious
ValuationCheap
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−16.67% from high₹70
₹5+1,373.68% from low₹84
Current
₹70.00
Prev close
₹70.04
Day
−0.06%
Price performance
1D
−0.06%
1W
−4.11%
1M
+9.20%
3M
+2.49%
6M
—
1Y
—
YTD
+2.49%
Financials
Revenue, profit & margin
P/E ratio
25.6×
SUNLOC is 25% below the sector median of 34.0×
SUNLOC25.6×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.70 | 22.67 | 21.31 | 21.50 | 20.26 | 20.46 | 21.20 | 22.64 | 23.52 | 21.84 | 19.72 | 18.99 | 19.22 | |
| YoY Sales growth | -22.65% | -9.97% | +0.24% | -4.49% | -14.51% | -9.75% | -0.52% | +5.30% | +16.09% | +6.74% | -6.98% | -16.12% | -18.28% | |
| Expenses | 22.48 | 23.30 | 18.63 | 19.29 | 17.95 | 17.76 | 18.17 | 19.37 | 19.59 | 18.22 | 17.78 | 16.06 | 16.92 | |
| Operating Profit | 1.22 | -0.63 | 2.68 | 2.21 | 2.31 | 2.70 | 3.03 | 3.27 | 3.93 | 3.62 | 1.94 | 2.93 | 2.30 | |
| OPM % | 5.15% | -2.78% | 12.58% | 10.28% | 11.40% | 13.20% | 14.29% | 14.44% | 16.71% | 16.58% | 9.84% | 15.43% | 11.97% | |
| Other Income | 0.22 | 3.13 | 0.68 | 0.14 | 0.18 | 0.53 | 0.49 | 0.86 | 0.42 | 0.50 | 0.29 | 0.23 | 1.19 | |
| Interest | 1.31 | 1.44 | 1.76 | 1.51 | 1.50 | 1.89 | 1.56 | 1.44 | 1.40 | 1.66 | 1.66 | 1.50 | 1.73 | |
| Depreciation | 1.59 | 1.45 | 1.43 | 1.48 | 1.51 | 1.69 | 1.68 | 1.66 | 1.64 | 1.62 | 1.52 | 1.46 | 1.46 | |
| Profit before tax | -1.46 | -0.39 | 0.17 | -0.64 | -0.52 | -0.35 | 0.28 | 1.03 | 1.31 | 0.84 | -0.95 | 0.20 | 0.30 | |
| Tax % | -25.34% | -48.72% | 5.88% | 6.25% | 7.69% | 57.14% | -28.57% | 11.65% | 23.66% | 30.95% | -258.95% | -130.00% | 20.00% | |
| Net Profit | -1.10 | -0.20 | 0.15 | -0.69 | -0.55 | -0.54 | 0.36 | 0.91 | 1.00 | 0.59 | 1.52 | 0.46 | 0.24 | |
| EPS in Rs | -1.07 | -0.20 | 0.15 | -0.67 | -0.54 | -0.53 | 0.35 | 0.89 | 0.98 | 0.58 | 1.48 | 0.45 | 0.23 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202673.53%Promoter
Promoters73.53%
DIIs0.10%
Public26.37%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Sunil Healthcare | ₹73.00 | 25.55 | 75 | 0.00% | 0 | −76.00% | 19 | −18.28% | 6.43% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts14
Credit ratings1
Announcements5
Approved Financial Results For The Quarter And Half Year Ended 30.09.2026 13 NovBoard Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2026 13 Nov - Board approved Q2/H1 FY27 unaudited standalone and consolidated results on Nov 13, 2026; independent director Rakesh Mohan's 2nd term ended.Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On 13Th November 2026 3 Nov - Board meeting on 13 Nov 2026 to approve Q2/H1 FY27 standalone and consolidated results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Oct - Reg. 74(5) compliance certificate for quarter ended September 30, 2026.Announcement under Regulation 30 (LODR)-Credit Rating 5 Oct - Brickwork upgraded long-term rating to BWRBBB- and short-term to BWR A3, effective 3 Oct 2026.






